[go: up one dir, main page]

WO2003035619A8 - Inhibiteurs de la tyrosine kinase - Google Patents

Inhibiteurs de la tyrosine kinase

Info

Publication number
WO2003035619A8
WO2003035619A8 PCT/US2002/033962 US0233962W WO03035619A8 WO 2003035619 A8 WO2003035619 A8 WO 2003035619A8 US 0233962 W US0233962 W US 0233962W WO 03035619 A8 WO03035619 A8 WO 03035619A8
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
tyrosine kinase
kinase inhibitors
present
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/033962
Other languages
English (en)
Other versions
WO2003035619A1 (fr
Inventor
B Wesley Trotter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of WO2003035619A1 publication Critical patent/WO2003035619A1/fr
Publication of WO2003035619A8 publication Critical patent/WO2003035619A8/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des composés capables d'inhiber, de moduler et/ou de réguler la transduction de signal de la tyrosine kinase de type récepteur et de type non récepteur. Les composés de la présente invention possèdent une structure de base comprenant un 2-carboxamidopyrrole. La présente invention concerne également des sels de qualité pharmaceutique, des hydrates et des stéréo-isomères de ces composés.
PCT/US2002/033962 2001-10-25 2002-10-21 Inhibiteurs de la tyrosine kinase Ceased WO2003035619A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34300001P 2001-10-25 2001-10-25
US60/343,000 2001-10-25

Publications (2)

Publication Number Publication Date
WO2003035619A1 WO2003035619A1 (fr) 2003-05-01
WO2003035619A8 true WO2003035619A8 (fr) 2003-07-03

Family

ID=23344243

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/033962 Ceased WO2003035619A1 (fr) 2001-10-25 2002-10-21 Inhibiteurs de la tyrosine kinase

Country Status (1)

Country Link
WO (1) WO2003035619A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8946278B2 (en) 2007-02-07 2015-02-03 Glaxosmithkline Llc Inhibitors of AkT activity

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2372363A1 (fr) 2005-09-20 2011-10-05 OSI Pharmaceuticals, Inc. Marqueurs biologiques prédictifs d'une réaction anticancéreuse aux inhibiteurs kinase du récepteur du facteur de croissance 1 analogue à l'insuline
EP2400985A2 (fr) 2009-02-25 2012-01-04 OSI Pharmaceuticals, LLC Thérapie anti-cancer combinée
JP2012519170A (ja) 2009-02-26 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 生体内の腫瘍細胞のｅｍｔステータスをモニターするためのｉｎｓｉｔｕ法
JP2012519281A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
WO2010099138A2 (fr) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Procédés pour l'identification d'agents qui inhibent les cellules tumorales de type mésenchymateuses ou leur formation
WO2010099364A2 (fr) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Méthodes d'identification d'agents qui inhibent les cellules cancéreuses mésenchymateuses ou leur formation
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
AU2011223643A1 (en) 2010-03-03 2012-06-28 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
JP2013520998A (ja) 2010-03-03 2013-06-10 オーエスアイ・ファーマシューティカルズ，エルエルシー インスリン様増殖因子−１受容体キナーゼ阻害剤に対する抗癌反応の予測に役立つ生物学的マーカー
WO2011112666A1 (fr) 2010-03-09 2011-09-15 OSI Pharmaceuticals, LLC Thérapie anticancéreuse combinatoire
US20120214830A1 (en) 2011-02-22 2012-08-23 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
EP2702173A1 (fr) 2011-04-25 2014-03-05 OSI Pharmaceuticals, LLC Utilisation de signatures de gènes de tem dans la découverte de médicaments contre le cancer, diagnostics et traitement du cancer
WO2013152252A1 (fr) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Polythérapie antinéoplasique
JP6255038B2 (ja) 2013-02-26 2017-12-27 トリアクト セラピューティクス，インク． 癌治療
US9381246B2 (en) 2013-09-09 2016-07-05 Triact Therapeutics, Inc. Cancer therapy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1139754A4 (fr) * 1998-12-31 2002-12-18 Sugen Inc Composes 3-heteroarylidenyl-2-indolinone utilises pour modulation de l'activite de la proteine kinase et dans la chimiotherapie du cancer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8946278B2 (en) 2007-02-07 2015-02-03 Glaxosmithkline Llc Inhibitors of AkT activity

Also Published As

Publication number Publication date
WO2003035619A1 (fr) 2003-05-01

Similar Documents

Publication Publication Date Title
WO2004014300A3 (fr) Inhibiteurs de la tyrosine kinase
WO2004014851A3 (fr) Inhibiteurs de tyrosine kinases
WO2003035615A3 (fr) Inhibiteurs de tyrosine kinase
WO2003035616A3 (fr) Inhibiteurs de la tyrosine kinase
WO2003035619A8 (fr) Inhibiteurs de la tyrosine kinase
WO2003035614A3 (fr) Inhibiteurs de la tyrosine kinase
WO2004031401A3 (fr) Nouveaux inhibiteurs de tyrosine kinases
WO2002046183A3 (fr) Composes de pyrroline substitues par l'indazolyle comme inhibiteurs de kinase
AU2001241798A1 (en) 3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors
WO2004096795A3 (fr) Inhibiteurs de la kinase c-fms
WO2000043373A3 (fr) Inhibiteurs de kinase
WO2001019828A3 (fr) Inhibiteurs de kinase utilises comme agents therapeutiques
AP1718A (en) 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors
WO2000002576A3 (fr) Egf-genistein utilise pour la prevention de la restenose
EP0766676A4 (fr) Composes et procede destines a inhiber la phosphodiesterase iv
MY141739A (en) Substituted quinazoline derivatives as inhibitors of aurora kinases
WO2001060814A3 (fr) Inhibiteurs de la proteine kinase 2-indolinone a substitution pyrrole
WO2004009597A3 (fr) Pyrazolopyrimidines en tant qu'inhibiteurs de kinases
AU2001288374A1 (en) Substituted oxindole derivatives as tyrosine kinase inhibitors
WO2006047503A3 (fr) Inhibiteurs de la c-fms kinase
WO2002081728A3 (fr) Inhibiteurs quinoline des kinases hyak1 et hyak3
WO2001056573A8 (fr) Utilisation d'inhibiteurs de cox-2 en tant qu'agents procinetiques gastriques
EP1390052A4 (fr) Inhibition de la kinase jun
WO2003037863A3 (fr) Indoles substitues, procede pour leur preparation et leur utilisation pour lutter contre la douleur
WO2003086315A3 (fr) Inhibiteurs de la tyrosine kinase

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 18/2003 UNDER (22) REPLACE "23 OCTOBER 2002 (23.10.2002)" BY "21 OCTOBER 2002 (21.10.2002)"

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP